Intellipharmaceutics Announces Third Quarter 2014 Results
October 15, 2014 16:45 ET
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics Announces Resignation of Chief Financial Officer
September 30, 2014 17:25 ET
|
Intellipharmaceutics International Inc.
TORONTO, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose Deterrence Technology
August 28, 2014 16:43 ET
|
Intellipharmaceutics International Inc.
TORONTO, Aug. 28, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics Announces Second Quarter 2014 Results
July 07, 2014 18:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, July 7, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and...
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement
May 20, 2014 17:45 ET
|
Intellipharmaceutics International Inc.
TORONTO, May 20, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and...
Intellipharmaceutics Announces First Quarter 2014 Results
April 14, 2014 07:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, April 14, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics -- Amended Form of Proxy for Shareholders Meeting to be Held on March 27, 2014
March 19, 2014 17:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, March 19, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics to Present at Two Upcoming Investor Conferences
March 04, 2014 17:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, March 4, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics Announces 2013 Year End Results
February 18, 2014 07:05 ET
|
Intellipharmaceutics International Inc.
TORONTO, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics Receives $3.1 Million From Par Pharmaceuticals, Inc.
February 03, 2014 07:00 ET
|
Intellipharmaceutics International Inc.
- First Profit-Share Payment on 15 and 30 mg Generic Focalin XR® Sales
TORONTO, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a...